JP2025118768A5 - - Google Patents
Info
- Publication number
- JP2025118768A5 JP2025118768A5 JP2025076698A JP2025076698A JP2025118768A5 JP 2025118768 A5 JP2025118768 A5 JP 2025118768A5 JP 2025076698 A JP2025076698 A JP 2025076698A JP 2025076698 A JP2025076698 A JP 2025076698A JP 2025118768 A5 JP2025118768 A5 JP 2025118768A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- sequence set
- isolated
- enhancer element
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801483P | 2019-02-05 | 2019-02-05 | |
| US62/801,483 | 2019-02-05 | ||
| US201962823281P | 2019-03-25 | 2019-03-25 | |
| US62/823,281 | 2019-03-25 | ||
| US201962916477P | 2019-10-17 | 2019-10-17 | |
| US62/916,477 | 2019-10-17 | ||
| PCT/US2020/015183 WO2020163102A1 (en) | 2019-02-05 | 2020-01-27 | Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating dravet syndrome |
| JP2021545659A JP7724157B2 (ja) | 2019-02-05 | 2020-01-27 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545659A Division JP7724157B2 (ja) | 2019-02-05 | 2020-01-27 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025118768A JP2025118768A (ja) | 2025-08-13 |
| JP2025118768A5 true JP2025118768A5 (https=) | 2025-12-26 |
Family
ID=71947919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545659A Active JP7724157B2 (ja) | 2019-02-05 | 2020-01-27 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
| JP2025076698A Pending JP2025118768A (ja) | 2019-02-05 | 2025-05-02 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545659A Active JP7724157B2 (ja) | 2019-02-05 | 2020-01-27 | ニューロン細胞興奮性の正常化およびドラベ症候群の処置のための介在ニューロン特異的治療剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220195457A1 (https=) |
| EP (1) | EP3921326A4 (https=) |
| JP (2) | JP7724157B2 (https=) |
| KR (1) | KR20210133227A (https=) |
| CN (1) | CN113966400A (https=) |
| CA (1) | CA3128525A1 (https=) |
| IL (1) | IL284909A (https=) |
| SG (1) | SG11202107813RA (https=) |
| WO (1) | WO2020163102A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115707773A (zh) * | 2021-08-20 | 2023-02-21 | 中国科学院深圳先进技术研究院 | 一种利用交感神经控制血管内皮细胞异质性的方法 |
| US12054486B2 (en) | 2021-09-24 | 2024-08-06 | Xenon Pharmaceuticals Inc. | Pyridine derivatives and their use as sodium channel activators |
| WO2023108401A1 (zh) * | 2021-12-14 | 2023-06-22 | 深圳先进技术研究院 | 重组载体及其构建方法和应用 |
| JP2024545923A (ja) | 2021-12-30 | 2024-12-13 | リーゲル セラピューティクス，インコーポレイティッド | ナトリウム電位依存性チャネルアルファサブユニット１の発現を調節するための組成物、及びその使用 |
| GB2621102A (en) * | 2022-04-11 | 2024-02-07 | Univ Ramot | Treatment and Reversion of Dravet syndrome by CAV-2-Mediated Delivery of an SCN1A Expression Cassette |
| WO2023200700A2 (en) * | 2022-04-11 | 2023-10-19 | The Broad Institute, Inc. | Enhancers for directed expression of genes in neuronal cell populations, compositions and methods thereof |
| CN116024222B (zh) * | 2022-11-30 | 2023-12-22 | 湖南家辉生物技术有限公司 | 一种导致婴儿严重肌阵挛性癫痫的nac1基因突变体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101255424B (zh) * | 2007-11-26 | 2013-02-27 | 广州医学院第二附属医院 | 与癫痫相关scn1a基因的启动子及其构建方法和临床应用 |
| EP2635111B1 (en) * | 2010-11-05 | 2018-05-23 | The Board of Trustees of the Leland Stanford Junior University | Stabilized step function opsin proteins and methods of using the same |
| US10682424B2 (en) * | 2015-03-31 | 2020-06-16 | New York University | Compositions and method for reducing seizures |
| MX2019011772A (es) * | 2017-04-03 | 2020-01-09 | Encoded Therapeutics Inc | Expresion transgenica selectiva de tejidos. |
-
2020
- 2020-01-27 KR KR1020217028274A patent/KR20210133227A/ko active Pending
- 2020-01-27 SG SG11202107813RA patent/SG11202107813RA/en unknown
- 2020-01-27 JP JP2021545659A patent/JP7724157B2/ja active Active
- 2020-01-27 US US17/428,538 patent/US20220195457A1/en active Pending
- 2020-01-27 WO PCT/US2020/015183 patent/WO2020163102A1/en not_active Ceased
- 2020-01-27 CN CN202080027324.8A patent/CN113966400A/zh active Pending
- 2020-01-27 EP EP20752944.7A patent/EP3921326A4/en active Pending
- 2020-01-27 CA CA3128525A patent/CA3128525A1/en active Pending
-
2021
- 2021-07-18 IL IL284909A patent/IL284909A/en unknown
-
2025
- 2025-05-02 JP JP2025076698A patent/JP2025118768A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025118768A5 (https=) | ||
| US11446398B2 (en) | Regulated biocircuit systems | |
| Basu et al. | Connexin 43/47 channels are important for astrocyte/oligodendrocyte cross-talk in myelination and demyelination: R Basu and J Das Sarma | |
| JP2020534788A5 (https=) | ||
| Fagoe et al. | Spinal cord injury and the neuron-intrinsic regeneration-associated gene program | |
| CA3033788A1 (en) | Nucleic acid products and methods of administration thereof | |
| JP2016538885A5 (https=) | ||
| JP2022519623A5 (https=) | ||
| EA025365B1 (ru) | Применение антитела к cd37 для лечения пациента из группы высокого риска, страдающего хроническим лимфолейкозом (cll), способ истощения экспрессирующих cd37 в-клеток в популяции клеток с дефицитом тр53 | |
| US20200206314A1 (en) | Hsv vectors for delivery of nt3 and treatment of cipn | |
| JP2025508337A5 (https=) | ||
| Safieh-Garabedian et al. | Targeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptide | |
| KR20250117489A (ko) | 항체 절단 효소를 포함하는 조성물 및 그의 사용 방법 | |
| Xiang et al. | ROS-activated CXCR2+ neutrophils recruited by CXCL1 delay denervated skeletal muscle atrophy and undergo P53-mediated apoptosis | |
| Zhang et al. | Thyroid hormone T4 mitigates traumatic brain injury in mice by dynamically remodeling cell type specific genes, pathways, and networks in hippocampus and frontal cortex | |
| EP4277987A1 (en) | Compositions for and methods of engineering the transcriptome | |
| Girotra et al. | Identification of multi-targeted anti-migraine potential of nystatin and development of its brain targeted chitosan nanoformulation | |
| EP4116418A1 (en) | Compound and method for an allele-specific editing of the elane gene | |
| JP2022543722A5 (https=) | ||
| Taravini et al. | Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats | |
| EP1007735A1 (en) | Anti-sense oligonucleotide pharmacological agents | |
| CN108473989A (zh) | Il-34反义寡核苷酸以及使用其的方法 | |
| US20140256795A1 (en) | Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration | |
| KR102685034B1 (ko) | 금속 나노 입자-핵산 결합체를 기반으로 하는 유전자 운반체 | |
| CN119998457A (zh) | 基于金属纳米颗粒-核酸缀合物的基因载体 |